Can we trust AI-generated RWD? A systematic validation approach in prostate cancer
As AI-generated real-world data (RWD) become increasingly integrated into evidence generation, demonstrating data quality is becoming just as important as developing the underlying models.
In this interview, Eunice Hankinson (Flatiron Health) discusses research presented at ISPOR 2026, where the newly published VALID Framework was applied to evaluate an LLM-extracted prostate cancer dataset.
In the interview, she explores:
- Why the VALID Framework was developed and the methodological challenge it addresses
- How structured validation extends beyond traditional accuracy metrics
- The difference between data quality and fitness-for-purpose
- Why transparent, repeatable validation is becoming increasingly important as AI-generated datasets are adopted across healthcare research
For professionals working across HEOR, RWE, HTA, market access, regulatory affairs, and healthcare data science, this interview is essential reading for understanding one of the key methodological questions surrounding the use of AI-generated RWD and how these datasets can be evaluated with greater transparency, consistency, and confidence.
About the interviewee
Eunice Hankinson
Senior Clinical Director, Flatiron Health
Eunice Hankinson, MSN, FNP-C, is a Senior Clinical Director at Flatiron Health. As a Nurse Practitioner with more than 11 years of experience in oncology clinical practice and research, she specializes in solid tumors, with particular expertise in genitourinary (GU) malignancies and Phase 1 clinical trials. She has deep expertise in RWD and RWE, including the development of comprehensive data models and the application of RWD to support evidence generation for use cases across the drug development lifecycle.
She received her Bachelor of Science from the State University of New York at Binghamton, and her Master of Science in Nursing from the University of Alabama at Birmingham. Prior to joining Flatiron Health, she served as the Lead Nurse Practitioner for Phase 1 Clinical Trials at MedStar Georgetown University Hospital.
Sponsorship for this Interview was provided by Flatiron Health.